La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Biomea Fusion Croissance future

Future contrôle des critères 2/6

Biomea Fusion devrait augmenter ses bénéfices et son chiffre d'affaires de 11.2% et de 82.1% par an respectivement. Le BPA devrait croître de de 8.8% par an. Le rendement des capitaux propres devrait être -107.1% dans 3 ans.

Informations clés

11.3%

Taux de croissance des bénéfices

10.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.0%
Taux de croissance des recettes	85.4%
Rendement futur des capitaux propres	-126.6%
Couverture par les analystes	Good
Dernière mise à jour	29 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

Aug 01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Jul 20

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Mar 16

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Nov 27

Biomea Fusion: Patience Warranted

Sep 23

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:BMEA - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	3	-169	-165	-134	7
12/31/2025	2	-150	-157	-119	7
12/31/2024	N/A	-147	-145	-120	7
6/30/2024	N/A	-140	-112	-111	N/A
3/31/2024	N/A	-127	-105	-105	N/A
12/31/2023	N/A	-117	-100	-97	N/A
9/30/2023	N/A	-108	-98	-94	N/A
6/30/2023	N/A	-102	-91	-87	N/A
3/31/2023	N/A	-95	-80	-76	N/A
12/31/2022	N/A	-82	-63	-62	N/A
9/30/2022	N/A	-71	-59	-58	N/A
6/30/2022	N/A	-61	-53	-50	N/A
3/31/2022	N/A	-52	-45	-41	N/A
12/31/2021	N/A	-42	-39	-35	N/A
9/30/2021	N/A	-30	-25	-22	N/A
6/30/2021	N/A	-19	-15	-14	N/A
3/31/2021	N/A	-11	-8	-8	N/A
12/31/2020	N/A	-5	-5	-4	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: BMEA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: BMEA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: BMEA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de BMEA ( 82.1% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de BMEA ( 82.1% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: BMEA devrait être non rentable dans 3 ans.

Biomea Fusion Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 17% to US$41.00

Price target increased by 10% to US$54.43

Price target decreased by 9.2% to US$49.38

Price target increased by 17% to US$48.63

Price target increased by 24% to US$27.50

Price target increased to US$23.60

Recent updates

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target increased by 17% to US$48.63

Biomea Fusion, Inc. Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association 83rd Scientific Sessions

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Price target increased by 24% to US$27.50

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (Covalent-111) Study of Bmf-219

Biomea Fusion, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes

Biomea Fusion, Inc. Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date

High number of new and inexperienced directors

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Biomea Fusion, Inc. Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Price target increased to US$23.60

Biomea Fusion, Inc. Announces First Patient Dosed with Chronic Lymphocytic Leukemia (Cll) in Covalent-101 Trial

FDA Clears Biomea's IND Application to Begin A Phase I/Ib Trial of BMF-219

Biomea Fusion Presents New Preclinical Data At the European Association for the Study of Diabetes (Easd) Annual Meeting Describing Bmf-219’S Potential as A Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

Biomea Fusion GAAP EPS of -$0.59 beats by $0.01

We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Growth Index

Biomea Fusion, Inc. Appoints Elizabeth Faust as Class I Director

Biomea Fusion, Inc. Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial

Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models At Ada 2022

Price target decreased to US$19.50

Biomea Fusion, Inc. Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$21.00

High number of new and inexperienced directors

Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting

High number of new and inexperienced directors

Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans

Biomea Plans to Initiate Enrollment of Patients with MM and Diffuse Large B-Cell Lymphoma (DLBCL) in the Ongoing Phase I Clinical Trial of BMF-219 in the First Half of 2022

Biomea Fusion, Inc. Appoints Steve Morris, M.D. as Chief Medical Officer

Biomea Fusion, Inc. Announces First Patient Dosed

CFO & Principal Accounting Officer recently bought US$87k worth of stock

Biomea Fusion, Inc. Announces 2022 Clinical Development Plan to Initiate Studies in Up to Seven Different Tumor Types and in Diabetes for BMF-219

Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

High number of new directors

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Biomea Fusion: Patience Warranted